SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Traders are fixated on the pending readout of Viking Therapeutics' VK2735 maintenance study, a dose-ranging trial testing extended dosing for maintenance after induction with the company's injectable GLP-1/GIP dual agonist for obesity. With results unreleased, the community is split: bulls argue the absence of a run-up into the data creates a better setup and point to heavy short interest as squeeze potential, while bears warn of a sell-the-news reaction and question whether the maintenance results can outdo Eli Lilly's Zepbound on efficacy and tolerability. Frustration over the company's undisclosed release timeline adds to the debate.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending after Coretura  the software-defined vehicle platform company founded by Daimler Truck and Volvo Group  selected Alloy Kore, the QNX-based software layer co-developed with Vector, marking the platform's first announced design win. Retail traders are largely bullish, with some citing a contract value reported in media coverage but absent from the company's press release, while skeptics note the deal covers only commercial vehicles and argue upcoming quarterly results and guidance matter more.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending following a decline triggered by concerns regarding the company's long-term growth outlook, potential patent expirations, and intense competition from Eli Lilly in the GLP-1 market. While the community remains divided over the CEO's leadership and strategic communication, many investors view the current valuation as an attractive opportunity for a long-term turnaround, highlighting the potential of the oral Wegovy franchise and future pipeline developments.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

The stalled Senate vote on the CLARITY Act is dominating Circle chatter, with the stock caught in a broader selloff among crypto-linked names including Coinbase as the industry weighs what comes next after the legislation failed to advance. Traders are parsing why the vote stalled  debate over the 60-vote Senate threshold, big-bank objections, and ethics concerns  around a bill that would have given the CFTC primary authority over much of the digital-asset industry. The community is split: bears see "no catalyst left" and an easy short, while bulls defend Circle's rate-sensitive revenue model, arguing higher short-term rates would boost the interest income earned on the Treasury securities and cash backing USDC. A secondary thread covers Circle's Arc blockchain launch, which some traders frame as a "sell the news" event despite its BlackRock and Visa backing, with additional discussion of the Tazapay acquisition.

On Holding AG engages in the development and distribution of sports products such as footwear, apparel, and accessories for high-performance running, outdoor, all-day activities, and tennis. It sells its products worldwide through independent retailers and global distributors, its own online presence, and its own stores. The company was founded by David Allemann, Olivier Bernhard, and Caspar Coppetti in January 2010 and is headquartered in Zurich, Switzerland.

On Holding AG - Ordinary Shares Class A

On Holding AG

On Holding is drawing heavy discussion around its investor day, where management laid out financial targets through 2029 and authorized the company's first share repurchase program. Traders are split, with bulls calling the targets conservative and speculating about a short squeeze given elevated short interest, while skeptics flag the buyback's modest size relative to Deckers and note the stock has continued sliding toward 52-week lows.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopify is trending on the sharp rally following its Q2 report, with traders split over whether the move holds. Results showed revenue of $3.58B versus roughly $3.44B consensus (34% growth) and GMV of $115.57B, and traders say stronger-than-expected Q3 guidance eased the AI-disruption fears that had kept the stock down year-to-date. The move has fueled heavy short-squeeze chatter, with bulls calling it a fight against shorts and dip-buyers saying the pullback risk is worth adding into. Bulls point to analyst backing circulating in the discussion  Bernstein initiating coverage at Outperform with a $160 target on the view that AI expands rather than hurts Shopify's opportunity, and Jefferies saying the quarter cleared a high bar. Bears counter that a ~$160B market cap is hard to justify, argue the beat leaned on unrealized gains and buybacks, and warn AI site-building tools could disintermediate the platform long term; several say they are shorting or taking profits. A minority blames macro noise  Fed rate-hike commentary and U.S.Canada tensions  for the volatility.

London-based Quant Network is set to revolutionise blockchain technology with the development of their blockchain operating system Overledger. The experienced team are determined to fulfil the original vision of the internet by creating an open trusted network for people, machines, and data to operate securely and safely.  Overledger -the first interoperable blockchain operating system that facilitates internet-scale development of decentralised, multi-chain applications. Overledger has the ability to unlock and distribute value and applications across current and future blockchains. It is an agnostic platform that connects the world's networks to blockchains and ensures you're not limited to any single a vendor or technology. Overledger is the only platform that facilitates the development of internet-scales development of decentralised, multi-chain applications.

Quant

Quantinuum's Nasdaq IPO under the same QNT ticker is driving the bulk of the conversation, with traders debating whether the listing has anything to do with the unrelated Quant token. Skeptics frame the token's strength as ticker confusion, while bulls point to its Robinhood listing, fixed low supply, and central-bank pilot work as independent drivers.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD's surge to record highs and its entry into the $1 trillion market-cap conversation are driving attention, with traders citing AI chip-demand optimism  including bets tied to Meta's Muse AI and chatter around the company's OpenAI partnership  as the force behind a run that has lifted shares more than 175% year-to-date and added hundreds of billions in market value. Retail sentiment has turned extremely bullish, and much of the discussion centers on short sellers being squeezed out of the rally, with repeated warnings that shorting the momentum is a losing bet while a few question how long it can climb on what they call 'speculation, no real numbers.' The debate splits between bulls who see AMD being re-rated as the key No. 2 AI chip supplier behind Nvidia amid industry-wide supply constraints, and skeptics pointing to roughly $2.65 in EPS against a $600-plus share price, rich valuation versus megacap peers, and claims of insider selling. Some traders are booking profits or taking small short positions, while others who missed the run describe chasing trillion-dollar-cap FOMO.

Maase, Inc. operates as a integrated provider and operator of artificial intelligence (AI) centric full-scene digital systems. The firm focus on areas of flexible energy deployment and intelligent commercial network operation, and provide closed-loop solutions from computing infrastructure, smart hardware and full-scene services, aiming to achieve large-scale implementation of AI technologies across industries. The company was founded by Hai Feng Yu on August 6, 2018 and is headquartered in Qingdao, China.

Maase Inc. - Ordinary Shares - Class A

Highest Performances Holdings Inc. - ADR

Traders are focused on Maase's rapid cadence of enterprise AI contract announcements  compute-capacity leases, prepaid token-based API agreements, and a larger 450P FP16 cluster deal with VirtAI Tech  which supporters frame as a shift from one-off projects toward recurring enterprise revenue. Bulls argue the stock is undervalued versus Western compute peers, while skeptics counter that announced contracts still need to convert into recognized revenue, margins, and cash collection, noting shares have pulled back despite the news flow amid rate-hike pressure on small-cap AI names.

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is rallying alongside Bitcoin's push to multi-month highs and has broken above its recent August peak, with the community split between bull-run euphoria from long-term holders and skeptics warning the move is overheated and due for a crash. Traders are also weighing the Senate's failure to advance the Clarity Act and the CFTC's pledge to issue its own crypto rules, with some calling the market reaction a knee-jerk dip and others a 'sell the news' event.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ultragenyx is drawing attention after the FDA approved its FAYUVI gene therapy for Sanfilippo syndrome Type A, the first approved treatment for the rare pediatric disorder, with the community also focused on the accompanying priority review voucher as a source of non-dilutive cash. Traders are divided between bulls citing buyout potential, undervaluation, and a possible short squeeze, and bears pointing to the muted price reaction, dilution fears, and continued cash burn.

RARE Stock Up 13% on FDA Approval of Sanfilippo Syndrome Gene Therapy

Ultragenyx jumps 13% after FDA approval of Fayuvi, the first approved treatment for Sanfilippo syndrome Type A, backed by durable clinical data.

Ultragenyx Gets A ‘Much-Needed Win,’ Says Cantor – Sees $400M Opportunity After FDA Approves Neurodegenerative Disease Therapy

Equity

Wall Street raised Ultragenyx’s price target after the U.S. Food and Drug Administration approved Fayuvi to treat children with Sanfilippo syndrome Type A.


Ultragenyx (RARE) Surges 12.6%: Is This an Indication of Further Gains?

Ultragenyx (RARE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Ultragenyx Pharmaceutical (RARE) Stock Jumps After Hours: Here's Why It Is Trending

Ultragenyx shares rise after hours following FDA approval of FAYUVI, the first treatment approved for Sanfilippo syndrome Type A.read more...

S&P 500, Nasdaq, Dow Set For Mixed Open? US Stock Futures Seek Direction After Fed's First Rate Hike In Three Years

On Thursday, all three benchmark indexes closed higher after a dip in oil prices and lower long-dated yields following the Fed’s rate-hike move. 

RARE Stock Jumps 13% — Extends Gains After-Hours As FDA Clears First Sanfilippo Gene Therapy

The Food and Drug Administration (FDA) granted full approval of Fayuvi, also known as UX111, for pediatric patients.


INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RAREPR NewswireNEW YORK, Sept. 17, 2026 NEW YORK, Sept. 17, 2026...

RARE Stock Hits Fresh 52-Week Low As Sanfilippo Drug Ruling Nears — Failed Angelman Syndrome Trial Weighs On Shares

RARE investors are now awaiting an FDA decision on UX111, the company’s one-time gene therapy for Sanfilippo syndrome type A.


Biotech Midweek Pulse: XBI Loses Steam After Hot 2026 Run — Here Are The Stocks And Catalysts To Watch Next

Large-cap healthcare outperformed this week: XLV gained 1.4% through Tuesday, while XBI fell 1.4% and IBB declined 0.5%.

RARE Stock Crashes In Worst Day Ever — ‘Pharma Bro’ Martin Shkreli Calls It ‘Very Cheap,’ Floats BioMarin Buyout 

Wall Street removed the Angelman program from valuation models, slashing price targets by as much as 76% and issuing multiple downgrades.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ultragenyx Pharmaceutical Inc.

Extremely Bullish Sentiment

Rising interest rates

Surging bond yields

Oil/energy volatility

Trump/political risk

U.S. investors are navigating a stacked macro backdrop, with the Federal Reserve hiking rates for the first time since July 2023, the 10-year Treasury yield hitting 5.00% - its highest level since 2007 - and oil prices swinging between $94 and $105 a barrel amid the ongoing U.S.-Iran conflict and Saudi pipeline disruptions. What's the biggest risk to your portfolio right now? Vote and explain your reasoning in the comments.

With the Fed hiking rates for the first time since 2023, the 10-year Treasury yield near 5%, and oil prices swinging on the U.S.-Iran conflict, what&#39;s the biggest risk to your portfolio right now?

Stocktwits

With the Fed hiking rates for the first time since 2023, the 10-year Treasury yield near 5%, and oil prices swinging on the U.S.-Iran conflict, what's the biggest risk to your portfolio right now?

Current Price	$14.65
Prev Close	$14.51
Open	$14.58
Dividend Yield	0.00%
50-Day Moving Average	$23.87
Beta	1.05
Avg. Volume	2.13M
PE Ratio	-2.51

52-Week High	$39.89
52-Week Low	$12.73
Market Capitalization	$1.43B
EPS (Annual)	-$5.83
Price to Book	-4.95
Revenue Per Employee	$490,882.57

Feed

News

Sentiment

Earnings

Fundamentals

Info

RARE Fundamentals